Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · IEX Real-Time Price · USD
5.56
-0.01 (-0.18%)
At close: Jul 19, 2024, 4:00 PM
5.57
+0.01 (0.18%)
Pre-market: Jul 22, 2024, 4:01 AM EDT
Aurinia Pharmaceuticals Employees
Aurinia Pharmaceuticals had 300 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
300
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$638,023
Profits / Employee
-$208,543
Market Cap
795.19M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 300 | 0 | - |
Dec 31, 2022 | 300 | 0 | - |
Dec 31, 2021 | 300 | 6 | 2.04% |
Dec 31, 2020 | 294 | 232 | 374.19% |
Dec 31, 2019 | 62 | 23 | 58.97% |
Dec 31, 2018 | 39 | 6 | 18.18% |
Dec 31, 2017 | 33 | 13 | 65.00% |
Dec 31, 2016 | 20 | 4 | 25.00% |
Dec 31, 2015 | 16 | 5 | 45.45% |
Dec 31, 2014 | 11 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Atrion | 712 |
Cytek Biosciences | 676 |
Clover Health Investments | 552 |
OrthoPediatrics | 247 |
Simulations Plus | 197 |
Olema Pharmaceuticals | 74 |
Abivax | 61 |
Immunome | 55 |
AUPH News
- 3 days ago - Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 - Business Wire
- 10 days ago - ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM - Business Wire
- 20 days ago - Aurinia to Participate in Upcoming Investor Healthcare Conferences - Business Wire
- 5 weeks ago - Aurinia Announces 2024 Annual General Meeting Results - Business Wire
- 6 weeks ago - Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 - Business Wire
- 6 weeks ago - Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce - Business Wire
- 6 weeks ago - Aurinia Provides Update on Proxy Statement - Business Wire
- 7 weeks ago - Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf - Business Wire